Trained as a neuroscientist, Rohit Nambisan is a product executive with experience leading product development organizations in pharma, medical devices, personalized medicine, health IT, healthcare data and analytics, and AI. Prior to co-founding and leading Lokavant, Rohit was most recently the Head of Digital Product at Roivant and the Head of Product at Prognos Health. Rohit holds an M.S in Management and Engineering from MIT, an M.A. in Neuroscience from Boston University, and a B.A in Cognitive Neuroscience from UC Berkeley.
Archives: Speakers
Travis Caudill
In my role, I am responsible for leading ICON’s country and site selection strategy ensuring that every project ICON undertakes benefits from a data-driven approach, optimized to reflect customer priorities, and with a probability of success calibrated to each customer’s risk preferences.
I started my journey working for a local health insurance company supporting actuarial (claims data) analysis, and then joined a local CRO to help them develop a data-driven site identification strategy to support their late phase studies. Since then I’ve held a number of Feasibility, Site Identification, and Study Start-up focused roles across midsize and large CROs.
I’m an expert in trial modelling and leveraging artificial intelligence to inform country and site selection. I have really enjoyed helping to develop ICON’s OneSearch platform as well as leading initiatives to deliver next-generation scenario planning capabilities. As we work to bring the best of both organizations together I’m excited about exploring new opportunities to excite and delight our customers through data-driven delivery.
Alberto Turra
Alberto has worked at the forefront of the structured products industry since 2009, starting his career at large international banks. In 2012 he joined Leonteq Securities in London, spearheading the firm distribution efforts in Russia and CEE while rising to the rank of Managing Director. In 2021 he was appointed Head of Sales London. He manages a team of 10 people whose mandates span from UK / Ireland to South Africa.
Sakis Paliouras
Laura Accettola
Laura currently serves as Vice President and Therapeutic Unit Head for Hematology and Oncology at PPD, part of Thermo Fisher Scientific. In this role she holds responsibilities for the strategic direction, business operations, and operational delivery for hematology and oncology Ph I-III clinical trials.
Laura brings with her more than 25 years from the pharma and biotech side with broad multinational experience across the product development lifecycle which includes global development, clinical operations, medical affairs, and value and access. Laura is passionate about improving the patient experience on clinical trials and delivering medicines in the most accessible ways.
Sandra Shpilberg
Sandra Shpilberg is the CEO & Co-founder of Adnexi, a software platform that helps biopharma identify the best trial sites (Site Intelligence), Key Opinion Leaders (KOL) and Digital Opinion Leaders (DOL) who can accelerate treatment development. Adnexi provides rapid, accurate, tech-enabled, customized, complete and continuously updating identification of trial sites, searching for prior experience that’s relevant to your trials. Prior to Adnexi, Sandra was the CEO & Founder of Seeker Health, a successful patient finding platform that was acquired by Eversana. Prior to being an entrepreneur, Sandra held executive roles at biopharma companies including BioMarin and Johnson & Johnson.
Gabriela Rosu
Gabriela Nicola Rosu, MD joined Worldwide Clinical Trials as an Executive Director, Medical Affairs, Oncology. She provides medical monitoring for solid tumor and hematologic malignancy clinical trials, and consults with clients on protocol development, and offering strategies for optimal study delivery and risk mitigation. Gabriela also provides therapeutic and protocol training to study teams and mentors medical staff as requested.
Prior to joining Worldwide, Gabriela was a Senior Medical Director for Premier Research, a role in which she provided medical monitoring for oncology clinical trials in lymphoma, myeloma, and GU, GI, GYN, thoracic, melanoma, and CNS indications. Dr. Rosu has extensive experience with Immuno-oncology compounds including toxicity management.
Dr. Rosu served as Chief Medical Officer for IMV Inc for nearly four years, in which she had responsibility for oncology clinical development, KOL development, and planning for scientific publications and presentations at regional and national meetings. Prior to this, she was Global Medical Adviser /International Medical Director for Novo Nordisk Healthcare where she supported hemophilia and coagulation disorder clinical trials and Global Medical Affairs.
Gabriela graduated from the University of Medicine and Pharmacy Gr.T. Popa in Iasi, Romania, obtaining the Doctor in Medicine diploma. After completing her medical education, she worked as a physician in several hospitals in Iasi, Romania. More recently, Gabriela obtained a Certificate of Achievement from Harvard Medical School in Immunology and Immuno-Oncology.
Gabriela maintains active memberships for ASCO, ESMO and ACHE
Mark Hollingworth
Mark leads the commercial partnership function at AccountsIQ, including working with financial outsourcing partners.
He has 20 years of experience in the accounting technology sector. During that time, he has consulted on accountancy software solutions and digital transformation across a broad range of practices; from top 4 firms to sole practitioners.
Clive Webb
Clive Webb is the Head of Business Management in ACCA’s Policy and Insights team. Clive publishes research on the future of the finance function across a wide range of topics from the purpose of the function to the skills that it needs and the technologies that it needs to apply. Clive is also the author of two research pieces, one which considered Diversity, Equity and Inclusion in the profession and the most recent the profession’s responsibility in the social agenda. Clive qualified as an accountant in one of the big 4.
